Barclays PLC Buys 5,142 Shares of Amedisys, Inc. (NASDAQ:AMED)

Barclays PLC grew its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 49.5% in the third quarter, HoldingsChannel reports. The firm owned 15,529 shares of the health services provider’s stock after buying an additional 5,142 shares during the quarter. Barclays PLC’s holdings in Amedisys were worth $1,500,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. KBC Group NV bought a new position in shares of Amedisys during the 3rd quarter valued at approximately $63,000. Signaturefd LLC lifted its position in Amedisys by 88.2% during the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after purchasing an additional 530 shares during the last quarter. CWM LLC grew its stake in shares of Amedisys by 14.5% in the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after buying an additional 277 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Amedisys in the 3rd quarter worth about $243,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Amedisys during the 2nd quarter valued at about $280,000. 94.36% of the stock is owned by institutional investors.

Amedisys Price Performance

NASDAQ:AMED opened at $89.96 on Friday. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of 35.70, a PEG ratio of 1.84 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The business has a 50 day simple moving average of $90.45 and a 200-day simple moving average of $94.43. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). The firm had revenue of $587.67 million for the quarter, compared to the consensus estimate of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.98 earnings per share. Equities analysts forecast that Amedisys, Inc. will post 4.45 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.